As shown that TDE-PD-L2 mediates the progression of ccRCC tumor (Fig. 4B–E), we hypothesized that antibodies targeting PD-L2 are able to restore effects of TDE-PD-L2 on ccRCC tumor progression. This evidence concerns the gene PDCD1LG2 and nonpapillary renal cell carcinoma.